Eversens — Other

Eversens, developer of the evernoa exhaled-biomarker analysers for airway inflammation, received an undisclosed investment structured as a convertible participative loan from CDTI Innovación (Innvierte programme) together with Orza and UN I+D+i Tech Transfer. The company said it is now seeking Series A financing to grow internationally, notably in the US.